Last updated on August 2020

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Brief description of study

The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (< 50 nanograms/deciliter [ng/dL]; 1.7 nanomoles/liter [nmol/L]) in participants with androgen-sensitive advanced prostate cancer.

Detailed Study Description

This is a phase 3, multinational, randomized, open-label, parallel group study to evaluate the efficacy and safety of oral daily relugolix 120 mg in participants with androgen-sensitive advanced prostate cancer who require at least 1 year of continuous androgen deprivation therapy. Relugolix 120 mg orally once daily or leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan based on local labels), every 3 months by subcutaneous injection will be administered to participants.

Approximately 1100 participants will be enrolled in this study, including approximately 390 participants with metastatic advanced prostate cancer to support the analysis of the secondary endpoint of castration resistance free survival and 138 Chinese participants (enrolled in China and Taiwan) to support registration in China.

There are 2 analyses for this study, a primary analysis and a final analysis. The primary analysis of efficacy and safety will occur after approximately 915 participants have been randomized to the study and evaluated for 48 weeks and completed the 30-day safety follow-up visit or discontinued early with 30-day safety follow-up. The final analysis will occur after approximately 390 participants with metastatic disease (or approximately 1100 participants with or without metastatic prostate cancer) have been randomized from any sites to the study. To support registration in China, the study will continue to enroll additional nonmetastatic or metastatic participants from China after the final analysis to reach the target enrollment of 138 participants.

Eligible participants will be randomized 2:1 to relugolix or leuprolide arm and will attend visits monthly (every 4 weeks) where serum testosterone and prostate-specific antigen will be assessed.

Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, and 12-lead electrocardiograms.

Clinical Study Identifier: NCT03085095

Find a site near you

Start Over


Chang chun, China
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.